Honors & Awards

  • Conquer Cancer Foundation of ASCO Abstract Award 2013, Conquer Cancer Foundation/ ASCO (April 2013)
  • A.P. Giannini Postdoctoral Fellowship, A.P. Giannini Foundation (March 2013- Current)
  • AACR- Aflac, Inc. Scholar Award, American Association for Cancer Research (February 2013)
  • Frontiers of Science/NCI Award, Keystone Symposia (February 2013)
  • Department of Pathology Research Retreat Presentation Award, Stanford University School of Medicine Department of Pathology (June 2012)
  • Stanford University School of Medicine Outstanding Student Teaching Award, Stanford University Office of Graduate Education (June 2011)
  • Philanthropic Educational Organization (P.E.O.) International Scholar Award, Philanthropic Educational Organization (P.E.O.) (March 2011)
  • AACR Women in Cancer Research Scholar Award, American Association for Cancer Research (April 2010)
  • National Science Foundation Graduate Research Fellowship, National Science Foundation (October 2010- Current)
  • BD Biosciences Innovative Research Award, BD Biosciences (March 2009)
  • American Society of Hematology Trainee Research Award, American Society of Hematology (2007,2008,2009)

Professional Education

  • Doctor of Philosophy, Stanford University, CANBI-PHD (2012)
  • Bachelor of Arts, University of California Berkeley, Mol and Cell Biology, Honors (2007)

Stanford Advisors


Graduate and Fellowship Programs


Journal Articles

  • Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature genetics Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., Crabtree, G. R. 2013; 45 (6): 592-601


    Subunits of mammalian SWI/SNF (mSWI/SNF or BAF) complexes have recently been implicated as tumor suppressors in human malignancies. To understand the full extent of their involvement, we conducted a proteomic analysis of endogenous mSWI/SNF complexes, which identified several new dedicated, stable subunits not found in yeast SWI/SNF complexes, including BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, BRD9 and SS18. Incorporating these new members, we determined mSWI/SNF subunit mutation frequency in exome and whole-genome sequencing studies of primary human tumors. Notably, mSWI/SNF subunits are mutated in 19.6% of all human tumors reported in 44 studies. Our analysis suggests that specific subunits protect against cancer in specific tissues. In addition, mutations affecting more than one subunit, defined here as compound heterozygosity, are prevalent in certain cancers. Our studies demonstrate that mSWI/SNF is the most frequently mutated chromatin-regulatory complex (CRC) in human cancer, exhibiting a broad mutation pattern, similar to that of TP53. Thus, proper functioning of polymorphic BAF complexes may constitute a major mechanism of tumor suppression.

    View details for DOI 10.1038/ng.2628

    View details for PubMedID 23644491

  • Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma CELL Kadoch, C., Crabtree, G. R. 2013; 153 (1): 71-85


    Recent exon sequencing studies have revealed that over 20% of human tumors have mutations in subunits of mSWI/SNF (BAF) complexes. To investigate the underlying mechanism, we studied human synovial sarcoma (SS), in which transformation results from the translocation of exactly 78 amino acids of SSX to the SS18 subunit of BAF complexes. We demonstrate that the SS18-SSX fusion protein competes for assembly with wild-type SS18, forming an altered complex lacking the tumor suppressor BAF47 (hSNF5). The altered complex binds the Sox2 locus and reverses polycomb-mediated repression, resulting in Sox2 activation. Sox2 is uniformly expressed in SS tumors and is essential for proliferation. Increasing the concentration of wild-type SS18 leads to reassembly of wild-type complexes retargeted away from the Sox2 locus, polycomb-mediated repression of Sox2, and cessation of proliferation. This mechanism of transformation depends on only two amino acids of SSX, providing a potential foundation for therapeutic intervention.

    View details for DOI 10.1016/j.cell.2013.02.036

    View details for Web of Science ID 000316853700007

    View details for PubMedID 23540691

  • Biology and Treatment of Primary Central Nervous System Lymphoma NEUROTHERAPEUTICS Algazi, A. P., Kadoch, C., Rubenstein, J. L. 2009; 6 (3): 587-597


    Primary central nervous system lymphoma (PCNSL) is a rare variant of extranodal non-Hodgkin lymphoma that is restricted in distribution to the brain, leptomeninges, spinal cord, and intraocular compartments. Although PCNSL shares overlapping features with systemic lymphoma, recent studies also reveal a unique pattern of gene and protein expression in PCNSL. These findings have yielded new insights into the pathophysiology of the disease, as well as the identification of novel prognostic biomarkers. Immune system compromise, such as is seen in acquired immune deficiency syndrome (AIDS), is the best established known risk factor for PCNSL. Like other lesions of the brain, meninges, and eye, the presenting symptoms associated with PCNSL typically include focal neurological deficits related to the site of disease or more global consequences of increased intracranial pressure. Diagnosis of PCNSL typically includes gadolinium-enhanced MRI and pathologic tissue analysis, as well as additional studies aimed at excluding concurrent systemic disease. PCNSL typically has a worse overall prognosis than systemic lymphoma. High-dose chemotherapy, particularly with methotrexate-based regimens, is the backbone of therapy for most patients, and chemotherapy is associated with much lower rates of treatment-related morbidity and mortality than whole-brain irradiation. Autologous stem cell transplantation is an emerging treatment modality, particularly in younger patients with relapsed disease, but high rates of treatment-related mortality are observed in older patients. Immunotherapy, including treatment with intrathecal rituximab, is another area of active research that may have promise in refractory or relapsed disease. Treatment options for intraocular lymphoma parallel those for PCNSL elsewhere in the brain: systemic chemotherapy, radiation, and local delivery of cytotoxic and immunologically active agents such as anti-CD20 antibody.

    View details for Web of Science ID 000267581800016

    View details for PubMedID 19560747

  • Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model CLINICAL CANCER RESEARCH Kadoch, C., Dinca, E. B., Voicu, R., Chen, L., Nguyen, D., Parikh, S., Karrim, J., Shuman, M. A., Lowell, C. A., Treseler, P. A., James, C. D., Rubenstein, J. L. 2009; 15 (6): 1989-1997


    The prospect for advances in the treatment of patients with primary central nervous system lymphoma (PCNSL) is likely dependent on the systematic evaluation of its pathobiology. Animal models of PCNSL are needed to facilitate the analysis of its molecular pathogenesis and for the efficient evaluation of novel therapeutics.We characterized the molecular pathology of CNS lymphoma tumors generated by the intracerebral implantation of Raji B lymphoma cells in athymic mice. Lymphoma cells were modified for bioluminescence imaging to facilitate monitoring of tumor growth and response to therapy. In parallel, we identified molecular features of lymphoma xenograft histopathology that are evident in human PCNSL specimens.Intracerebral Raji tumors were determined to faithfully reflect the molecular pathogenesis of PCNSL, including the predominant immunophenotypic state of differentiation of lymphoma cells and their reactive microenvironment. We show the expression of interleukin-4 by Raji and other B lymphoma cell lines in vitro and by Raji tumors in vivo and provide evidence for a role of this cytokine in the M2 polarization of lymphoma macrophages both in the murine model and in diagnostic specimens of human PCNSL.Intracerebral implantation of Raji cells results in a reproducible and invasive xenograft model, which recapitulates the histopathology and molecular features of PCNSL, and is suitable for preclinical testing of novel agents. We also show for the first time the feasibility and accuracy of tumor bioluminescence in the monitoring of a highly infiltrative brain tumor.

    View details for DOI 10.1158/1078-0432.CCR-08-2054

    View details for Web of Science ID 000264511000021

    View details for PubMedID 19276270

  • Differential gene expression in central nervous system lymphoma BLOOD Rubenstein, J. L., Shen, A., Batchelor, T. T., Kadoch, C., Treseler, P., Shuman, M. A. 2009; 113 (1): 266-267

    View details for Web of Science ID 000262162800036

    View details for PubMedID 19122120

  • Protein biomarker identification in the CSF of patients with CNS lymphoma JOURNAL OF CLINICAL ONCOLOGY Roy, S., Josephson, S. A., Fridlyand, J., Karch, J., Kadoch, C., Karrim, J., Damon, L., Treseler, P., Kunwar, S., Shuman, M. A., Jones, T., Becker, C. H., Schulman, H., Rubenstein, J. L. 2008; 26 (1): 96-105


    Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease. We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients. We used enzyme-linked immunosorbent assay (ELISA) to confirm one of these markers in an additional validation set of 101 cases.Approximately 80 CSF proteins were identified and found to be present at significantly different concentrations, both higher and lower, in training and test studies, which were highly concordant. To further validate these observations, we defined in detail the expression of one of these candidate biomarkers, antithrombin III (ATIII). ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature. Determination of ATIII concentration by ELISA was significantly more accurate (> 75% sensitivity; > 98% specificity) than cytology in the identification of cancer. Measurement of CSF ATIII levels was found to potentially enhance the ability to diagnose and predict outcome.Our findings demonstrate for the first time that proteomic analysis of CSF yields individual biomarkers with greater sensitivity in the identification of cancer than does CSF cytology. We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.

    View details for DOI 10.1200/JCO.2007.12.1053

    View details for Web of Science ID 000254176800020

    View details for PubMedID 18056677

  • Molecular pathogenesis of primary central nervous system lymphoma. Neurosurgical focus Kadoch, C., Treseler, P., Rubenstein, J. L. 2006; 21 (5): E1-?


    Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma (NHL) typically associated with a worse prognosis than other localized extranodal lymphomas with similar histological characteristics. The defining feature of PCNSL is its confinement to the central nervous system (CNS), with proclivity for growth within the leptomeningeal as well as intraocular compartments. Primary CNS lymphoma rarely disseminates outside the CNS and accounts for less than 5% of all primary brain neoplasms. At least 95% of PCNSLs are of large B-cell histology, the most common subtype of NHL. Consistent with the trend seen in systemic NHLs, the incidence of PCNSL has markedly increased over the past three decades, both in immunocompromised and immunocompetent patients. Because PCNSL is relatively rare, the identification of molecular prognostic biomarkers and the definition of a standard therapeutic strategy have been challenging. The authors discuss the current knowledge of the molecular pathogenesis of CNS lymphomas and review the recent advances in gene expression profile analysis and identification of novel prognostic biomarkers.

    View details for PubMedID 17134111

  • When prostate brachytherapy fails: A case report and discussion ONCOLOGIST Kadoch, C., D'Amico, A. V., Matthews, R. H. 2005; 10 (10): 799-805


    For appropriately selected brachytherapy patients, prostate-specific antigen failure is uncommon. Our patient experienced biochemical failure after 125I brachytherapy treatment for low-risk prostate adenocarcinoma. We suggest neoadjuvant/adjuvant hormonal therapy combined with pelvic external-beam radiation therapy as a reasonable salvage treatment. At the 2-year follow-up, he is apparently doing well. With limited data available, salvage management for this situation is presently investigational.

    View details for Web of Science ID 000234014900004

    View details for PubMedID 16314290

Stanford Medicine Resources: